logo
Sign in

Insight Genetics, Inc.

NASHVILLE, TN · Still private

Claim this profile

Follows are private to you and power your alerts

Updated

Headquarters
NASHVILLE, TN
Latest Form D
$3M, Nov 2015
Total capital
$8.1M
Federal grants
$5.1M
6 awards · 2010–2013
Private capital raised
$3M
2 Form D · last Nov 2015
132 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
14 pending · first 2016

Capital timeline

201020112012201320142015FEDERAL ↑EQUITY ↓Cumulative $10.6M$200K$194K$1.5M$200K$1.5M$1.5M1st Form D$2.5M
201020112012201320142015FEDERAL ↑EQUITY ↓Cumulative $10.6M$200K$1.5M$1.5M$1.5M1st Form D$2.5M

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$3M
  • Offering registeredForm D · SEC · 1st filing$2.5M
  • Federal grantHealth and Human S · N44 · Development of a Clincial Diagnostic Assay for ALK Inhibitor Mutations$1.5M
  • Federal grantHealth and Human S · N44 · Other Functions Development Of A Companion Diagnostic For Alk Mutations.$1.5M
  • Federal grantHealth and Human S · N43 · Other Functions - R&d Biomedical (basic Research)$200K
  • Federal grantHealth and Human S · N01 · Other Functions - R&d Biomedical (basic Research)$1.5M
  • Federal grantHealth and Human S · N43 · TAS::75 0849::TAS SBIR Topic 277 - Development Of A Clinical Diagnostic Assay Fo$194K
Show 1 earlier federal award
  • Federal grantHealth and Human S · N43 · Companion Diagnostic for ALK Mutations$200K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

49months

from Insight Genetics, Inc.’s first federal award to its first private round.

First federal award · Sep 2010
Health and Human S · $200K
First Form D · Oct 2014
$2.5M · 1st Form D
Awards before first raise
6 awards

An association in public records, not a cause or a prediction.

Founders and team

Researcher links verified by same-company patents and grants
  • David A. HoutResearcherExecutive OfficerLinked by $5.1M in grants as PI
  • Christopher T. CallaghanExecutive Officer, DirectorNamed in SEC Form D filings
  • Eric B. DahlhauserExecutive Officer, DirectorNamed in SEC Form D filings
  • Paul A. DahlhauserDirectorNamed in SEC Form D filings
  • Richard T. IsaacsonDirectorNamed in SEC Form D filings
  • Richard A. WattsDirectorNamed in SEC Form D filings
Show all 9 people
  • Rob A. SeitzExecutive OfficerNamed in SEC Form D filings
  • Ronnie A. AndrewsDirectorNamed in SEC Form D filings
  • Stephan A. MorrisExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 15
  • PendingMethods And Compositions Relating To Fusions Of Alk For Diagnosing And Treating CancerUSPTOApplication 15334974
  • GrantedKit Comprising Primers For Amplifying Alk Kinase Domain Nucleic AcidsUSPTOUS 9,428,812
  • PendingMethods And Compositions Relating To Next Generation Sequencing For Genetic Testing In Alk Related CancersUSPTOApplication 14431430
Show all 15 patent records
  • Methods And Compositions Relating To Fusions Of Alk For Diagnosing And Treating CancerJun 29, 2017 · Application 15334974Pending
  • Kit Comprising Primers For Amplifying Alk Kinase Domain Nucleic AcidsAug 30, 2016 · US 9,428,812Granted
  • Methods And Compositions Relating To Next Generation Sequencing For Genetic Testing In Alk Related CancersAug 27, 2015 · Application 14431430Pending
  • Methods And Compositions Relating To Diagnosing And Treating Receptor Tyrosine Kinase Related CancersAug 20, 2015 · Application 14383735Pending
  • Methods And Compositions Relating To Alk For Diagnosing And Treating Inflammatory Breast And Other Human CancersApplication PCTUS2013054375Pending
  • Methods And Compositions Relating To Diagnosing And Treating Receptor Tyrosine Kinase Related CancersApplication PCTUS2013029969Pending
  • Methods And Compositions Relating To Fusions Of ROS1 For Diagnosing And Treating CancerApplication PCTUS2013025345Pending
  • Methods And Compositions Relating To Fusions Of Alk For Diagnosing And Treating CancerApplication PCTUS2010035147Pending
  • Methods Of Screening Nucleic Acids For Single Nucleotide VariationsApplication PCTUS2008006191Pending
  • Methods And Compositions For The Diagnosis And Treatment Of Cancers Resistant To ROS1 InhibitorsApplication 14777010Pending
  • Methods and Compositions Relating to ALK for Diagnosing and Treating Inflammatory Breast and Other Human CancersApplication 14420532Pending
  • Methods And Compositions Relating To Fusions Of ROS1 For Diagnosing And Treating CancerApplication 14377387Pending
  • Methods And Compositions Relating To Fusions Of Alk For Diagnosing And Treating CancerApplication PCTUS2015027886Pending
  • Methods And Compositions For The Diagnosis And Treatment Of Cancer ROS1 InhibitorsApplication PCTUS2014027720Pending
  • Methods And Compositions Relating To Next Generation Sequencing For Genetic Testing In Alk Related CancersApplication PCTUS2013061950Pending

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .